EUVIMEDEUVIMED entdecken
Crossref

Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method

European Journal of Haematology · 2024

DOI: 10.1111/ejh.14130 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, 2024. Hauptthemen laut MEDLINE: Hemophilia A, Glycoproteins.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AGlycoproteinsHumansHalf-LifeFactor VIIIRecombinant ProteinsTreatment Outcome

Substanzen

simoctocog alfa (Nuwiq)Factor VIIIRecombinant ProteinsGlycoproteins

Zitieren

APA

(2024). Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method. European Journal of Haematology. https://doi.org/10.1111/ejh.14130

Vancouver

Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method. European Journal of Haematology. 2024. doi:10.1111/ejh.14130

BibTeX
@article{euvimed2024,
  title = {Clinical efficacy of simoctocog alfa versus extended half‐life recombinant FVIII concentrates in hemophilia A patients undergoing personalized prophylaxis using a matching‐adjusted indirect comparison method},
  journal = {European Journal of Haematology},
  year = {2024},
  doi = {10.1111/ejh.14130}
}
Kostenlos starten →